Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16262)	9/14/2003 2:34:22 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Nice but, why not say how much was spent? we know that the $80 million owed represent 12.5% of total cost. Some has been repaid but $640 is pretty close. Why not start trying to prove to shareholders that Xoma is trying to level with them and be more transparent? Also, did you see Xoma is supposedly going to pay 25% of the marketing cost!! Is that correct or is that what Xoma agreed to to get the 90 day grace period on repayment. As we know Xoma was getting 25% of the gross profits but paid only 12.5% of development cost. Is it now 25% of marketing? $14 million in 2004!! Wow and Xoma throws away $45 million because it can't tell Wall Street that it not they make the decisions! You should clear up the 25% stuff. Nice article but just a local paper.

To: Bluegreen who wrote (16262)	9/14/2003 7:03:56 PM
From: Bluegreen	Respond to of 17367

Now this is a part of the article I hope is correct>>>>>>>Castello said Xoma has no plans for new financing deals in 2004, but is in serious discussions with other firms regarding potential new partnerships. As soon as the FDA approves the drug, Xoma intends to begin testing four or five other uses for Raptiva, Castello said. Those would include other autoimmune diseases, such as lupus, multiple sclerosis and organ transplantation. "It's really a case of which to choose next," Castello said. Xoma dropped studies of Raptiva for kidney transplantation, but the company, Castello said, could pick that up again, perhaps in "a year or so." Xoma and Genentech also hope to have data on a Phase II trial of Raptiva for psoriatic arthritis by the end of the year, and then determine whether to enter Phase III trials. Separately, Xoma plans to enter the clinic this fall with two others drugs, one for acne and another for vascular inflammation. "We're going to be a busy bunch," Castello said.<<<<<<<<<<<<<<<<<<< Busy bunch............has a real nice ring to it.